AVDL Avadel Pharmaceuticals Plc

Price (delayed)

$9.41

Market cap

$551.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.99

Enterprise value

$628.11M

Avadel Pharmaceuticals plc is a biopharmaceutical company primarily focused on the development and FDA approval of FT218, an investigational, once-nightly, extended-release formulation of sodium oxybate designed to treat excessive daytime ...

Highlights
AVDL's quick ratio is down by 45% since the previous quarter but it is up by 38% year-on-year
The gross profit has shrunk by 100% QoQ and by 100% YoY
The revenue has plunged by 100% from the previous quarter and by 100% YoY

Key stats

What are the main financial stats of AVDL
Market
Shares outstanding
58.6M
Market cap
$551.39M
Enterprise value
$628.11M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.63
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$59.85M
EBITDA
-$58.71M
Free cash flow
-$63.01M
Per share
EPS
-$0.99
Free cash flow per share
-$1.08
Book value per share
$2.03
Revenue per share
$0
TBVPS
$4.54
Balance sheet
Total assets
$282.59M
Total liabilities
$163.71M
Debt
$143.86M
Equity
$118.88M
Working capital
$214.42M
Liquidity
Debt to equity
1.21
Current ratio
14.17
Quick ratio
12.46
Net debt/EBITDA
-1.31
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-18.4%
Return on equity
-38%
Return on invested capital
-17.7%
Return on capital employed
-22.5%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AVDL stock price

How has the Avadel Pharmaceuticals stock price performed over time
Intraday
2.62%
1 week
18.36%
1 month
15.89%
1 year
87.45%
YTD
40.87%
QTD
39.82%

Financial performance

How have Avadel Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$64.77M
Net income
-$56.01M
Gross margin
N/A
Net margin
N/A
The gross profit has shrunk by 100% QoQ and by 100% YoY
The revenue has plunged by 100% from the previous quarter and by 100% YoY

Growth

What is Avadel Pharmaceuticals's growth rate over time

Valuation

What is Avadel Pharmaceuticals stock price valuation
P/E
N/A
P/B
4.63
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The stock's price to book (P/B) is 61% more than its last 4 quarters average of 2.8 but 36% less than its 5-year quarterly average of 7.1
The company's equity fell by 35% YoY and by 13% QoQ
The revenue has plunged by 100% from the previous quarter and by 100% YoY

Efficiency

How efficient is Avadel Pharmaceuticals business performance
The ROE has plunged by 182% YoY

Dividends

What is AVDL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AVDL.

Financial health

How did Avadel Pharmaceuticals financials performed over time
The total assets is 73% more than the total liabilities
Avadel Pharmaceuticals's current ratio has decreased by 47% from the previous quarter but it has increased by 38% YoY
AVDL's quick ratio is down by 45% since the previous quarter but it is up by 38% year-on-year
The debt is 21% greater than the equity
Avadel Pharmaceuticals's debt to equity has soared by 73% YoY and by 15% from the previous quarter
The company's equity fell by 35% YoY and by 13% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.